🟢 Tvardi Therapeutics is trading 5.8% up in pre-market with no clear catalyst identified

Tvardi Therapeutics is trading 5.8% up in pre-market at $1.09, versus the $1.03 October 9 close; no clear catalyst has been identified.

• The move follows a recent declining run.
• The company’s investor-relations page lists its latest release as September 24, about preclinical ulcerative-colitis data, and shows no October 9–12 release. Broad indexes are mixed, and available evidence does not establish a market-wide reason for the gain.